A virtual molecular
tumor board.
Give it a full oncology case — pathology, radiology, genomics, labs and clinical notes — and 55+ specialist agents deliberate in parallel to produce a fully-cited, guideline-concordant treatment recommendation with documented dissent.
Six layers from raw data to a signed-off plan
A medallion data pipeline feeds a hybrid knowledge layer; a LangGraph-style supervisor orchestrates 55+ agents across seven tiers; a synthesis-and-safety round challenges the consensus before any human sees it.
Why a risk-conscious clinical leader leans forward
Multimodal by construction
Imaging, genomics and text are first-class inputs fused into a shared case state — not bolted on.
Human-in-the-loop
The graph pauses at defined checkpoints for clinician sign-off. CADUCEUS never decides.
Provenance or it didn't happen
A Citation Validator rejects any recommendation lacking a traceable source. No source, no statement.
Adversarial self-check
A Dissent / Red-Team agent and a Contradiction Checker attack the consensus before a human sees it.
Privacy by design
Synthetic for the demo; real data de-identified and credentialed. A De-identification Verifier guards against PHI leakage.
Graded evidence
Recommendations carry levels of evidence (GRADE / NCI PDQ), not bare assertions.
Select a case to convene the board
Three synthetic / de-identified oncology presentations, each exercising a distinct reasoning path — oncogene-addicted targeted therapy, HER2 antibody therapy, and MSI-high immunotherapy.
Non-Small Cell Lung Cancer (adenocarcinoma)
64F never-smoker, EGFR exon 19-deleted lung adenocarcinoma, stage IV with solitary brain metastasis.
Breast Carcinoma (HER2-positive, HR-positive)
58F with HER2-positive, ER-positive invasive ductal carcinoma, de novo metastatic to liver and bone.
Colorectal Adenocarcinoma (BRAF V600E, MSI-high)
71M with right-sided colon adenocarcinoma, BRAF V600E mutant, mismatch-repair deficient (MSI-high), metastatic to liver.
Or run the board on a real patient
These pull real, de-identified cancer patients from the NCI Genomic Data Commons (TCGA) open tier in real time — no API key, no credentialing. Variants are annotated live against CIViC, drug safety from openFDA, trials from ClinicalTrials.gov, literature from Europe PMC. Honest data gaps are marked, never fabricated.
Lung adenocarcinoma (TCGA)
A real TCGA-LUAD patient with an EGFR kinase-domain driver — the board derives EGFR-TKI options live from CIViC.
Colon adenocarcinoma (TCGA)
A real TCGA-COAD patient with BRAF V600E — exercises the cross-disease evidence-transfer dissent (melanoma vs colorectal).
Breast carcinoma (TCGA)
A real TCGA-BRCA patient with an activating PIK3CA hotspot — PI3K-pathway actionability surfaced from CIViC.